Netherlands· NL-e63d3591b081
KAVIGALE 300 mg oplossing voor injectie/infusie
A sipavibart product containing sipavibart, registered in Netherlands by AstraZeneca AB. The same ATC class is registered in 7 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Sipavibart is registered in 7 of 19 countries.
Countries holding a registration under ATC J06BD09 (sipavibart), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 4 of them publish a price we can compare per daily dose
Sipavibart · ATC J06BD09
7 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- SIPAVIBART
- Manufacturer
- AstraZeneca AB
- Country
- Netherlands (NL)
- ATC code
- J06BD09
- ATC class
- Sipavibart
- Defined daily dose
- 0.3 g, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/24/1900
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sipavibart in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumKavigale 300 mgAstraZeneca
- CzechiaKAVIGALEAstraZeneca AB, Södertälje
- SpainKAVIGALE 300 MG SOLUCION INYECTABLE Y PARA PERFUSIONAstrazeneca Ab
- FinlandKAVIGALEAstraZeneca AB
- IrelandKAVIGALE 300 mg solution for injection/infusionAstraZeneca AB
- IcelandKavigaleAstraZeneca AB
- PolandKavigaleAstraZeneca AB
- SwedenKAVIGALE 300 mg Injektions-/infusionsvätska, lösningAstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Kavigale
- Liechtenstein · Kavigale
- Norway · Kavigale
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8ca88f84-57c2-4394-9f7b-1501381affcb GET /v1/drugs/8ca88f84-57c2-4394-9f7b-1501381affcb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie of infusie",
"route": "Intraveneus gebruik, Subcutaan gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/kavigale-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Sipavibart",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp133686",
"excipients": [
"ARGININEHYDROCHLORIDE, (L-)",
"HISTIDINE, (L-)",
"HISTIDINEMONOHYDROCHLORIDE 1-WATER (L-)",
"POLYSORBAAT 80 (E 433)",
"WATER VOOR INJECTIE"
],
"substances": [
"SIPAVIBART"
],
"leaflet_url": null,
"authorised_at": "2025/01/20",
"procedure_number": "EMEA/H/C/006291",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/24/1900",
"additional_monitoring": "Y"
}See everything about sipavibart.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.